In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Kiran Musunuru(Cardiovascular Institute of the South), Alexandra C. Chadwick(Verve Therapeutics (United States)), Taiji Mizoguchi(Verve Therapeutics (United States)), Sara P. Garcia(Verve Therapeutics (United States)), Jamie E. DeNizio(Verve Therapeutics (United States)), C.W. Reiss(Verve Therapeutics (United States)), Kui Wang(Verve Therapeutics (United States)), Sowmya Iyer(Verve Therapeutics (United States)), Chaitali Dutta(Verve Therapeutics (United States)), Victoria Clendaniel(Verve Therapeutics (United States)), Michael Amaonye(Verve Therapeutics (United States)), Aaron Beach(Verve Therapeutics (United States)), Kathleen Berth(Verve Therapeutics (United States)), Souvik Biswas(Verve Therapeutics (United States)), Maurine Braun(Verve Therapeutics (United States)), Huei-Mei Chen(Verve Therapeutics (United States)), Thomas V. Colace(Verve Therapeutics (United States)), John D. Ganey(Verve Therapeutics (United States)), Soumyashree A. Gangopadhyay(Verve Therapeutics (United States)), Ryan Garrity(Verve Therapeutics (United States)), Lisa N. Kasiewicz(Verve Therapeutics (United States)), Jennifer Lavoie(Verve Therapeutics (United States)), James A. Madsen(Verve Therapeutics (United States)), Yuri Matsumoto(Verve Therapeutics (United States)), Anne Marie Mazzola(Verve Therapeutics (United States)), Yusuf S. Nasrullah(Verve Therapeutics (United States)), Joseph Nneji(Verve Therapeutics (United States)), Huilan Ren(Verve Therapeutics (United States)), Athul Sanjeev(Verve Therapeutics (United States)), Madeleine Shay(Verve Therapeutics (United States)), Mary R. Stahley(Verve Therapeutics (United States)), Steven H.Y. Fan(Acuitas Therapeutics (Canada)), Ying K. Tam(Acuitas Therapeutics (Canada)), Nicole M. Gaudelli(Beam Therapeutics (United States)), Giuseppe Ciaramella(Beam Therapeutics (United States)), Leslie E. Stolz(Verve Therapeutics (United States)), Padma Malyala(Verve Therapeutics (United States)), Christopher J. Cheng(Verve Therapeutics (United States)), Kallanthottathil G. Rajeev(Verve Therapeutics (United States)), Ellen Rohde(Verve Therapeutics (United States)), Andrew M. Bellinger(Verve Therapeutics (United States)), Sekar Kathiresan(Verve Therapeutics (United States))
Cited by 755